163 related articles for article (PubMed ID: 16440269)
1. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
2. Bortezomib for myeloma -- much ado about something.
Dispenzieri A
N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
[No Abstract] [Full Text] [Related]
3. Review. Clinical pharmacokinetics of bortezomib.
Levêque D; Carvalho MC; Maloisel F
In Vivo; 2007; 21(2):273-8. PubMed ID: 17436576
[TBL] [Abstract][Full Text] [Related]
4. [Proteasome inhibitors].
Hatake K; Mishima Y; Terui Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
[TBL] [Abstract][Full Text] [Related]
5. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
Expert Rev Anticancer Ther; 2001 Dec; 1(4):509-10. PubMed ID: 12113081
[No Abstract] [Full Text] [Related]
7. [Proteasome inhibitor bortezomib as an anticancer drug].
Yasui H; Hideshima T
Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
[No Abstract] [Full Text] [Related]
8. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
Kukreja A; Hutchinson A; Mazumder A; Vesole D; Angitapalli R; Jagannath S; O'connor OA; Dhodapkar MV
Br J Haematol; 2007 Jan; 136(1):106-10. PubMed ID: 17222199
[TBL] [Abstract][Full Text] [Related]
9. [Proteasome inhibitors for multiple myeloma].
Yano H; Iida S
Nihon Rinsho; 2007 Jan; 65 Suppl 1():601-4. PubMed ID: 17476759
[No Abstract] [Full Text] [Related]
10. Bortezomib in multiple myeloma.
Meisler AI
N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
[No Abstract] [Full Text] [Related]
11. Images in clinical Medicine. Bortezomib-induced skin lesions.
Agterof MJ; Biesma DH
N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
[No Abstract] [Full Text] [Related]
12. Bortezomib in multiple myeloma.
Faix JD
N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14507954
[No Abstract] [Full Text] [Related]
13. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A
Leuk Res; 2006 Feb; 30(2):240-1. PubMed ID: 16081156
[No Abstract] [Full Text] [Related]
14. Perspective on the current use of bortezomib in multiple myeloma.
San-Miguel J; Bladé J
Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272
[No Abstract] [Full Text] [Related]
15. The proteasome--an emerging therapeutic target in cancer.
Mitchell BS
N Engl J Med; 2003 Jun; 348(26):2597-8. PubMed ID: 12826633
[No Abstract] [Full Text] [Related]
16. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib.
Paramore A; Frantz S
Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
[No Abstract] [Full Text] [Related]
18. Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
Politou M; Naresh K; Terpos E; Crawley D; Lampert I; Apperley JF; Rahemtulla A
Acta Haematol; 2005; 114(3):170-3. PubMed ID: 16227683
[No Abstract] [Full Text] [Related]
19. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
[No Abstract] [Full Text] [Related]
20. New developments with bortezomib in treating multiple myeloma.
Reddy GK
Clin Lymphoma; 2004 Mar; 4(4):215-6. PubMed ID: 15072611
[No Abstract] [Full Text] [Related]
[Next] [New Search]